Christiana Care CCOP was originally funded by NCI in 1987 and has continued to be an exemplary participant since that time. It was organized to facilitate participation in CALG6, NSABP and CCG clinical trials by community physicians in the region. Since inception ECOG, RTOG, CTSU, Wake Forest, Fox Chase and the University of Michigan Cancer Center have been added as research bases. Our extensive catchment area includes all of Delaware and portions of New Jersey, northeastern Maryland and southeastern Pennsylvania (Delaware and Chester Counties). Delaware ranks 34th in the nation for all cancer sites, Maryland ranks 32nd, New Jersey 34th, and Pennsylvania 36th. Our CCOP represents a population base in excess of 2.5 million people with extensive protocol entry potential. During the period June 1, 2005 through February 28, 2006 a total of 217 participants were accrued to treatment protocols (194.5 credits) and 80 participants to cancer control trials (42.8 credits). Under the leadership of Stephen Grubbs, M.D., Principal Investigator, and Kandie Price, MS, RN, Director, CCOP investigators, project coordinators and data managers continue to participate in Core Committees of CALGB, NSABP, RTOG, and COG. Over the last several years accrual to both treatment and cancer control studies has continued to increase and our CCOP has been recognized by the National Cancer Institute for its significant contributions to the program. The overall impact of this grant will be to assure continuation and stimulate expansion of CCOP activities, including treatment and cancer control research, at Christiana Care Health Services and its affiliates throughout our catchment area. 240 treatment and 160 cancer control credits will be accrued during the next grant year. ? ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
O'Mara, Ann M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Christiana Care Health Services, Inc.
United States
Zip Code
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340
Williams, Michael E; Hong, Fangxin; Gascoyne, Randy D et al. (2016) Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol 173:867-75
Morrison, Vicki A; Jung, Sin-Ho; Johnson, Jeffrey et al. (2015) Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma 56:958-64
Rugo, Hope S; Barry, William T; Moreno-Aspitia, Alvaro et al. (2015) Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N0 J Clin Oncol 33:2361-9
Voorhees, Peter M; Orlowski, Robert Z; Mulkey, Flora et al. (2015) Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Br J Haematol 171:373-7
Lilenbaum, Rogerio; Samuels, Michael; Wang, Xiaofei et al. (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). J Thorac Oncol 10:143-7
Beumer, Jan H; Owzar, Kouros; Lewis, Lionel D et al. (2014) Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol 74:927-38
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21

Showing the most recent 10 out of 100 publications